In the group of clinically localised ccRCC, the LOH in the CDKN2A region was associated with a higher risk of recurrence or development of metastatic disease, as determined by univariate analysis (p = 0.023; HR 4.04). Here, CDKN2A is linked to metastatic neoplasm.